Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018138185) NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/138185 International Application No.: PCT/EP2018/051783
Publication Date: 02.08.2018 International Filing Date: 25.01.2018
IPC:
C07K 14/005 (2006.01) ,G01N 33/569 (2006.01) ,G01N 33/574 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
01
DNA viruses
03
Herpetoviridae, e.g. pseudorabies virus
05
Epstein-Barr virus
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
569
for micro-organisms, e.g. protozoa, bacteria, viruses
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT [DE/DE]; Robert-Rössle-Straße 10 13125 Berlin, DE
Inventors:
BLANKENSTEIN, Thomas; DE
GAVVOVIDIS, Ioannis; DE
Agent:
KUTTENKEULER, David; Boehmert & Boehmert Pettenkoferstrasse 22 80336 Munich, DE
Priority Data:
17153038.925.01.2017EP
Title (EN) NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
(FR) NOUVEAUX RÉCEPTEURS DE LYMPHOCYTES T ET THÉRAPIE IMMUNITAIRE LES UTILISANT POUR LE TRAITEMENT DU CANCER ET DE MALADIES INFECTIEUSES
Abstract:
(EN) The present invention pertains to antigen recognizing constructs against antigens of the Merkel cell polyomavirus (MCV). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the infected host cells and tumor cell expressed MCV derived antigens. The TCR of the invention, and antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
(FR) La présente invention concerne des constructions de reconnaissance d'antigènes contre des antigènes du polyomavirus à cellules de Merkel (MCV). L'invention concerne particulièrement, de nouvelles molécules basées sur le récepteur des lymphocytes T (TCR) qui sont sélectives et spécifiques pour des cellules hôtes infectées et des antigènes dérivés du MCV exprimés par les cellules tumorales. Le TCR de l'invention, et les fragments de liaison à l'antigène dérivés de celui-ci, sont utiles pour le diagnostic, le traitement et la prévention de maladies cancéreuses. L'invention concerne en outre des acides nucléiques codant pour les constructions de reconnaissance d'antigène de l'invention, des vecteurs comprenant ces acides nucléiques, des cellules recombinantes exprimant les constructions de reconnaissance d'antigène et des compositions pharmaceutiques comprenant les composés de l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)